Gilead to Charge Hundreds Per Vial for Remdesivir

Trump administration says it secured new supplies of the drug for use against COVID-19

An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf in Hamburg, Germany, on April 8, 2020. Ulrich Perrey/Pool via Reuters, file Photo

A California-based company is charging hundreds of dollars per vial for a drug it created that’s shown promise against COVID-19.

Gilead Sciences announced Monday it will begin to charge for remdesivir in July, which it previously donated for free to the United States and other countries.